M A Palladino

Summary

Affiliation: Nereus Pharmaceuticals
Country: USA

Publications

  1. ncbi Anti-TNF-alpha therapies: the next generation
    Michael A Palladino
    Nereus Pharmaceuticals, 10480 Wateridge Circle, San Diego, California 92121, USA
    Nat Rev Drug Discov 2:736-46. 2003
  2. ncbi Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials
    B C Potts
    Nereus Pharmaceuticals, Inc, 10480 Wateridge Circle, San Diego, CA 92121, USA
    Curr Cancer Drug Targets 11:254-84. 2011
  3. ncbi A new family of synthetic diterpenes that regulates cytokine synthesis by inhibiting IkappaBalpha phosphorylation
    Ta-Hsiang Chao
    Nereus Pharmaceuticals, Inc, 10480 Wateridge Circle, San Diego, CA 92121, USA
    Chembiochem 6:133-44. 2005
  4. ncbi Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents
    Thanh Lam
    Department of Chemistry and Biochemistry, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0358, USA
    Bioorg Med Chem Lett 13:3217-21. 2003
  5. ncbi NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model
    James C Cusack
    Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Clin Cancer Res 12:6758-64. 2006

Research Grants

  1. TTL - A NEW CLASS OF ORAL TNF-ALPHA SYNTHESIS INHIBITORS
    Michael Palladino; Fiscal Year: 2002

Collaborators

  • M Groll
  • B Bonavida
  • Ta-Hsiang Chao
  • B C Potts
  • Thanh Lam
  • G K Lloyd
  • James C Cusack
  • Chinmay Chowdhury
  • Emmanuel A Theodorakis
  • Lyle L Moldawer
  • C Berkers
  • D J McConkey
  • M X Albitar
  • W Fenical
  • M A Spear
  • E Valashi
  • C P Miller
  • C M Sloss
  • F Pajonk
  • S Baritaki
  • P R Jensen
  • H Ovaa
  • J C Cusack
  • I M Ghobrial
  • P G Richardson
  • J Chandra
  • A Younes
  • K C Anderson
  • S T C Neuteboom
  • W McBride
  • K S Lam
  • D Chauhan
  • A M Roccaro
  • Y Oki
  • Ta Hsiang Chao
  • Vito J Palombella
  • Saskia T C Neuteboom
  • Rong Liu
  • Wei Niu
  • Christine Pien
  • Lijun Xia
  • Binh G Vong
  • F Rena Bahjat
  • Sonsoles Hortelano
  • G Kenneth Lloyd
  • F R Bahjat
  • Taotao Ling

Detail Information

Publications5

  1. ncbi Anti-TNF-alpha therapies: the next generation
    Michael A Palladino
    Nereus Pharmaceuticals, 10480 Wateridge Circle, San Diego, California 92121, USA
    Nat Rev Drug Discov 2:736-46. 2003
    ..In this review, we discuss briefly the present understanding of TNF-alpha-mediated biology and the current injectable therapies in clinical use, and focus on some of the new therapeutic approaches with oral, small-molecule inhibitors...
  2. ncbi Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials
    B C Potts
    Nereus Pharmaceuticals, Inc, 10480 Wateridge Circle, San Diego, CA 92121, USA
    Curr Cancer Drug Targets 11:254-84. 2011
    ..This review captures the remarkable translational studies and contributions from many collaborators that have advanced marizomib from seabed to bench to bedside...
  3. ncbi A new family of synthetic diterpenes that regulates cytokine synthesis by inhibiting IkappaBalpha phosphorylation
    Ta-Hsiang Chao
    Nereus Pharmaceuticals, Inc, 10480 Wateridge Circle, San Diego, CA 92121, USA
    Chembiochem 6:133-44. 2005
    ..These findings imply that these diterpenes represent promising leads for the development of novel anti-inflammatory agents...
  4. ncbi Synthesis of a novel family of diterpenes and their evaluation as anti-inflammatory agents
    Thanh Lam
    Department of Chemistry and Biochemistry, University of California-San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0358, USA
    Bioorg Med Chem Lett 13:3217-21. 2003
    ..Among them, methyl ester 12 exhibited a low non-specific cytotoxicity, inhibited TNF-alpha synthesis and displayed good specificity in suppressing cytokine expression...
  5. ncbi NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model
    James C Cusack
    Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Clin Cancer Res 12:6758-64. 2006
    ....

Research Grants1

  1. TTL - A NEW CLASS OF ORAL TNF-ALPHA SYNTHESIS INHIBITORS
    Michael Palladino; Fiscal Year: 2002
    ..The potential use of TTL-3 alone or in combination with other anti-inflammatory therapies opens new clinical and marketing opportunities. ..